Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Danish pharmaceutical company Novo Nordisk on Tuesday launched its once-weekly injectable weight-loss drug Wegovy in India, at Rs 4,336.25 per dose. Wegovy, a once-weekly glucagon-like peptide-1 ...

Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

TUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.